The Rationale: Last Reported Quarter and Management Outlook for Bridger Aerospace Group Holdings, Inc. (NASDAQ:BAER)
In the quarter ended June 30, 2026, totalRevenuewas negative USD 1.5 million, reflecting drug product revenue of negative USD 1.577 million, against USD 1.3 million a year earlier. Loss from operations widened to USD 17.6 million from USD 12.1 million and interest expense was …
The Rationale: Last Reported Quarter and Management Outlook for ClearSign Technologies Corporation (NASDAQ:CLIR)
For the quarter ended June 30, 2026, totalRevenuewas USD 187,546, compared with negative USD 21,172 a year earlier, with cost of revenues of USD 319,889. Selling, general and administrative expense was USD 2,593,671, while research and development expense, net of grant offsets of about …
In the second quarter of 2026 revenue was USD 229.1 million, down 4.1% on a currency neutral basis. Creative revenue was USD 127.4 million and other revenue fell to USD 5.2 million from USD 15.7 million. Annual Subscription revenue reached 58.8% of the total, …
The second quarter of 2026 showed lower operating spending. Research and development expense was USD 1.8 million against USD 3.1 million, general and administrative expense rose 8% to USD 1.7 million from USD 1.6 million, and the loss from operations was USD 3.5 million. …
Key Highlights358,530 is the USD in sales reported by Data Storage Corporation (NASDAQ:DTST) for the second quarter of 2026, up 9.3% from USD 327,951 a year earlier, withGross Profitrising to USD 168,481 from USD 138,182.9.3 million is the USD held in cash, cash equivalents …
Second quarter operating expenses were USD 4,594 thousand against USD 7,031 thousand a year earlier, including a provision forCreditlosses of USD 2,059 thousand and general and administrative expense of USD 1,723 thousand. Management gives no formal financial guidance and framed its outlook as priorities …
The operating loss was USD 11.1 million in the second quarter and USD 23.7 million for six months. Research and development expense was USD 3.9 million, down 73% year over year, and USD 11.9 million for six months, down 45%. Management expects significant losses …
The Rationale: Last Reported Quarter and Management Outlook for Vivos Therapeutics, Inc. (NASDAQ:VVOS)